PredictCan Biotechnologies has been selected as a Boost Invest MedVallée awardee following the presentation of its development strategy to the MedVallée Montpellier expert committee on December 4, 2025.
The selection represents an important milestone for PredictCan and recognizes the progress achieved by the company in developing a new generation of individual-centric preclinical models designed to bring human biological diversity into drug development.
Four Years of Scientific and Technological Development
Since its creation, PredictCan has built a strong scientific and technological foundation around its proprietary Cell Educating Technology™ and its applications in drug safety, efficacy, and precision medicine.
Over four years, the team has reached several key milestones, including four scientific publications and two patents, while advancing the development and validation of its human-relevant preclinical platform.
PredictCan has also expanded its activities internationally through strategic collaborations across Europe, North America, and Asia and its participation in an international consortium involving the U.S. FDA. These initiatives support the company’s ambition to develop preclinical approaches that are simultaneously more predictive of human response and less dependent on animal experimentation.
Preparing PredictCan’s Next Stage of Growth
Beyond its scientific achievements, the Boost Invest selection recognizes PredictCan’s development strategy and potential for growth.
The next stage of the company’s development is focused on accelerating the industrialization and adoption of its technology, expanding its drug safety and efficacy activities, strengthening international partnerships, and establishing PredictCan’s individual-centric approach as a new tool for preclinical decision-making.
By enabling drug candidates to be evaluated across diverse human biological profiles before clinical trials, PredictCan aims to help pharmaceutical and biotechnology companies better prioritize compounds, anticipate efficacy and toxicity differences, and reduce risk during drug development.
Supported by the MedVallée Ecosystem
As a Boost Invest awardee, PredictCan will benefit from the support of MedVallée Montpellier as the company advances its fundraising and growth strategy.
This recognition represents another step in PredictCan’s transition from scientific and technological validation toward broader industrial deployment, supporting its ambition to make human diversity a standard consideration in preclinical drug development.
